TY  - JOUR
AU  - Herbst, Roy S
AU  - Arkenau, Hendrik-Tobias
AU  - Santana-Davila, Rafael
AU  - Calvo, Emiliano
AU  - Paz-Ares, Luis
AU  - Cassier, Philippe A
AU  - Bendell, Johanna
AU  - Penel, Nicolas
AU  - Krebs, Matthew G
AU  - Martin-Liberal, Juan
AU  - Isambert, Nicolas
AU  - Soriano, Andres
AU  - Wermke, Martin
AU  - Cultrera, Jennifer
AU  - Gao, Ling
AU  - Widau, Ryan C
AU  - Mi, Gu
AU  - Jin, Jin
AU  - Ferry, David
AU  - Fuchs, Charles S
AU  - Petrylak, Daniel P
AU  - Chau, Ian
PY  - 2019
DO  - 10.1016/S1470-2045(19)30458-9
UR  - http://hdl.handle.net/10668/14239
T2  - The Lancet. Oncology
AB  - Pre-clinical and clinical evidence suggests that simultaneous blockade of VEGF receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances antigen-specific T-cell migration, antitumour activity, and has favourable toxicity. In this study, we aimed to assess the...
LA  - en
KW  - Adenocarcinoma
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents, Immunological
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Carcinoma, Transitional Cell
KW  - Dose-Response Relationship, Drug
KW  - Esophageal Neoplasms
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Stomach Neoplasms
TI  - Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
TY  - research article
VL  - 20
ER  -